Abstract: A sustained release solid oral dosage form for treatment of a psychotic disorder, for example schizophrenia, in a mammal is provided, which oral dosage form comprises ziprasidone in an amount effective in treating said psychotic disorder and a pharmaceutically acceptable carrier.

Abstract: Aqueous solubility of drugs including insoluble or poorly soluble drugs such as ziprasidone is improved using a functional polymer to form an ionic conjugate with said drug.

Abstract: Pharmaceutical formulations comprising: a compound selected from the group consisting of ziprasidone, having a maximum average particle size; a carrier; and preferably at least two surface stabilizers are disclosed. The present invention also comprises methods of treating psychosis with such a formulation and processes for making such a formulation.

Abstract: Pharmaceutical formulations comprising: a compound selected from the group consisting of ziprasidone, having a maximum average particle size; a carrier; and preferably at least two surface stabilizers are disclosed. The present invention also comprises methods of treating psychosis with such a formulation and processes for making such a formulation.

Abstract: Pharmaceutical formulations comprising: a compound of low water solubility, having a maximum average particle size; a carrier; and at least two surface stabilizers are disclosed. The present invention also comprises methods of treating various conditions with such a formulation and processes for making such a formulation.

Abstract: A liquid phase conjugate formed of a bioactive agent such as a drug compound, e.g. ziprasidone, and a liquid polymer of requisite functionality is disclosed.

Abstract: A pharmaceutical kit for preparing an injectable depot formulation of an aryl-heterocyclic pharmaceutical compound, such as ziprasidone, and a method of preparing said depot formulation is disclosed.

Abstract: Aqueous solubility of drugs including insoluble or poorly soluble drugs such as ziprasidone is improved using a functional polymer to form an ionic conjugate with said drug.

Abstract: An injectable depot formulation that is viscous, or becomes viscous in situ, comprising a solubilized aryl-heterocyclic pharmaceutical compound, such as ziprasidone, is provided.

Abstract: A method to administer a drug locally to a subject in which biodegradable dosage forms that contain the drug are implanted at a localized site beneath the skin of the subject whereupon the dosage forms release the drug over a desired period of time at a substantially continuous rate. Glyceryl monostearate based compositions that accomplish the method are also provided. Compositions are further provided that affect the release profile or release duration of drugs that are released from the compositions, as are methods that employ these varying release profiles to provide implantable dosage forms that release drugs at a prescribed rate over a prescribed period of time. The compositions are particularly well adapted to implantable dosage forms because they biodegrade quickly to an acceptable level after delivering the drug.